Drreddys Laboratories | RDY - Cost Of Sales


Drreddys Laboratories reported INR40.46B in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
ANI Pharmaceuticals USD 114.5M 8.38M Mar/2026
Aurora Cannabis CAD 88.61M 30.53M Dec/2025
Bayer EUR 5.23B 731M Mar/2026
Canopy Growth CAD 53.08M 8.3M Dec/2025
Cipla INR 26.32B 2.79B Mar/2026
Corcept Therapeutics USD 2.88M 338K Mar/2026
Drreddys Laboratories INR 40.46B 3.64B Dec/2025
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Lonza CHF 2.28B 189M Jun/2025
Novartis USD 3.46B 83M Mar/2026
Pacira USD 50.74M 3.89M Mar/2026
Phibro Animal Health USD 240.42M 2.58M Dec/2025
Prestige Brands USD 140.76M 9.53M Mar/2026
Richter Gedeon HUF 71.32B 1.01B Sep/2025
Sun Pharmaceuticals INR 36.77B 348M Dec/2025
Supernus Pharmaceuticals USD 49.04M 1.5M Mar/2026
Teva Pharmaceutical Industries USD 2.01B 46M Mar/2026